Qiming Wang

机构：Shenyang University of Technology, Zhengzhou University, Anshan Normal University, Shanghai Ninth People's Hospital, Henan Cancer Hospital · ORCID：0009-0002-3863-0262

发表论文 145 篇 · 总被引 1528 次 · h-index 19

代表论文

• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial (2025 · Nature Medicine · 被引 34)
• Hydrogeochemical mechanism and interconversion processes of groundwater-surface water in the Chan River Basin: A new perspective from hydrochemistry and isotopes (2025 · Journal of Environmental Sciences · 被引 18)
• Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 16)
• The Combination of Aligned PDA‐Fe@PLCL Conduit with Aligned GelMA Hydrogel Promotes Peripheral Nerve Regeneration (2024 · Advanced Healthcare Materials · 被引 16)
• Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma (2025 · Signal Transduction and Targeted Therapy · 被引 12)
• A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC. (2025 · Journal of Clinical Oncology · 被引 10)